Exosens · EURONEXT:EXENS
Exosens — H1 2024 Earnings Presentation
37 slides from Exosens's earnings presentation, Sep 3, 2024
Slide 1: H1 2024 Results
H1 2024 Results September 3rd , 2024 © EXOSENS restricted & confidential
Slide 2: Disclaimer
DISCLAIMER Certain information included in this presentation are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding Exosens’ present and future busi
Slide 3: Today's presenters
Today’s presenters Jérôme Cerisier Quynh-Boi Demey Chief Executive Officer Chief Financial Officer © EXOSENS restricted & confidential 3
Slide 4: I. Exosens introduction
I. Exosens introduction © EXOSENS restricted & confidential
Slide 5: We provide innovative technology for a safer world
Our purpose We provide innovative amplification, detection and imaging technology components © EXOSENS restricted & confidential for a safer world 5
Slide 6: We are a global leader in Amplification and Detection & Imaging
We are a global leader in Amplification and Detection & Imaging LEADER Top 1-2 player Highly attractive IN NICHE in most of addressed markets €3.2bn TAM markets: Defense, Industrial GROWING (~71% market share in Light Amplification, (~8% CAGR 2023-27) MARKETS1 ~24% in core addressed detection market
Slide 7: Exosens is focused on critical components driving end-user product performance
Exosens is focused on critical components driving the performance of products for end-users Business unit Key products Light Electronic Defense Amplification Amplification Intensifier tubes Lifescience Detection Imaging Digital cameras Industrial Detection Imaging control Digital cameras © EXOSENS r
Slide 8: What we want to achieve
What we want to achieve Be a leading technology platform across the particle and light spectrum… …cross-fertilising fast-growing markets and high value technologies… …through innovation, global commercial reach and selective acquisitions… …with balanced revenue between Amplification and Detection &
Slide 9: Key highlights of H1 2024
Key highlights of H1 2024 Strong financial Revenues of €186.9m, +50% vs. H1 2023, and +35% organic growth growth Increasing Adjusted EBITDA of €56.1m (vs. €34.0m for H1 2023) margin EBITDA margin of 30.0% (+278bps vs. H1 2023) Decreasing leverage 1.3x total net debt / adjusted EBITDA as at June 30th
Slide 10: II. Update on Exosens' key markets
markets II. Update on Exosens’ key © EXOSENS restricted & confidential
Slide 11: Key drivers of our markets
Key drivers of our markets Amplification Detection & Imaging Industrial control: Intense conventional warfare in Ukraine • Increasing devices performance US protectionist measures Rise of tensions in • Better product quality control Iran and Lebanon Rise of China military strength and presence • Fas
Slide 12: Focus on Night Vision
Amplification Detection & Imaging Focus on Night Vision Significant spending increase in Europe supported by resurgence of international threats NV market remains robust Key tactical advantage of night operation ability for high density combat with sustainable growth Acquisition rates across segment
Slide 13: Countries prioritize large scale night fighting capabilities
Amplification Detection & Imaging Countries prioritize large scale night fighting capabilities following Ukraine war and high intensity conflict comeback • Ukraine war main lessons are that territorial claims tend to be resolved by man to man combat highlighting criticality of night fighting capabil
Slide 14: NATO & Tier users still need to procure ~50% of needed NV devices
Amplification Detection & Imaging NATO & Tier 1 users still need to procure ~50% of needed NV devices above our market view after 5 years, ensuring long-term growth of Exosens addressed market Core addressed market - USA excluded (€m) Growth relies on forecasted investment and increase of equipment
Slide 15: Our D&I components serve markets with strong secular growth
Amplification Detection & Imaging Our D&I components serve markets benefitting from strong secular growth Semiconductor Electrical Machine vision Gas detection Lifescience N uclear Defense Science inspection Power • Battery • C limate change inspection issue • Genomic and • D riven by IoT, • D riven
Slide 16: III. H1 results
III. H1 results © EXOSENS restricted & confidential
Slide 17: Excellent H1 performance, driven by organic growth and margin expansion
Excellent H1 performance, driven by organic growth and margin expansion H1 2023 H1 2024 Change % of % of In €m In €m sales sales Revenue 125.0 186.9 49.5% Gross margin1 56.6 45.3% 91.1 48.8% 61.0% Indirect costs (22.6) (18.0%) (35.0) (18.7%) 55.1% Adjusted EBITDA 34.0 27.2% 56.1 30.0% 64.9% Deprecia
Slide 18: Continued growth momentum, revenues up 50%
Continued growth momentum, revenues up 50% Revenue (in €m) Growth vs. FY guidance +35% organic Total Organic 50% 19.0 186.9 44.1 (1.2) 35% ~30% 125.0 High teens © EXOSENS restricted & confidential 1 H1 2023 Amplification D&I I/C elimination H1 2024 YoY growth FY 2024 YoY growth FY 2024 guidance guid
Slide 19: Focus on segments
Focus on segments Amplification Detection & Imaging Revenue: Gross margin (% margin): Revenue: Gross margin (% margin): 138.5 44.6% 47.1% 45.8% 51.1% 94.3 75.2 Q2 65.2 +18.8% 42.1 50.4 31.5 25.8 63.3 Q1 26.2 Q2 14.4 +8.3% 24.2 Q1 H1 2023 H1 2024 H1 2023 H1 2024 H1 2023 H1 2024 H1 2023 H1 2024 Strong
Slide 20: Profitability increases significantly at group level and across both segments
Profitability increases significantly at group level and across both segments In €m % margin Margin expansion drivers Gross margin: Total Amplification D&I 91.1 +350bps +247bps +527bps 56.6 25.8 14.4 45.3% 48.8% 44.6% 47.1% 45.8% 51.1% 65.2 42.1 0.0 H1 2023 0.1 H1 2024 H1 23 H1 24 H1 23 H1 24 H1 23
Slide 21: Continued investment in R&D to remain at the edge of technology
Continued investment in R&D to remain at the edge of technology R&D (€m) Comments Gross R&D as% of sales 8.0% 7.9% Increase of R&D spent by €3.5m of which +€1.6m from innovation projects (prior to Net R&D1 as % of sales 6.7% 6.3% proof of concept) and +€1.9m scope Increase of customer co-investments
Slide 22: Capex optimization plan under way, now at 7% of sales
Capex optimization plan under way, now at 7% of sales Capex excluding R&D capitalised (€m) Comments Start of normalisation of capex after % of sales 8.8% 7.0% investment for capacity done in 2022 and 2023 6.4% 3.9% Higher investment in Maintenance to optimise existing assets and support future margi
Slide 23: Solid cash flow generation during H1 2024
Solid cash flow generation during H1 2024 In €m H1 2023 H1 2024 Comments Adjusted EBITDA 34.0 56.1 Capitalised R&D (4.3) (4.6) Adjusted EBITDA post Cap. R&D 29.7 51.5 €23.6m FCF in the period, of which €22m organic and €1.6m from scope effect Change in WC (13.2) (7.7) Tax paid (3.0) (1.6) Other inco
Slide 24: Our capital structure fully supports our growth strategy
Our capital structure fully supports our growth strategy In €m 30-Jun-24 Comments Term loan 250.0 Borrowings details: Other bank debt 3.6 • Debt fully refinanced at IPO in June, with the current structure comprising IFRS 16 lease liabilities 9.9 of: ‒ €250m term loan, maturing in Total gross debt 26
Slide 25: IV. Conclusion & outlook
IV. Conclusion & outlook © EXOSENS restricted & confidential
Slide 26: Significant growth, profitability and cash conversion improvement
Significant growth, profitability and cash conversion improvement: fully on track to deliver our guidance Strong start of the year with a growth of 49.5% growth (+€61.9m), driven by: Acceleration of revenue growth • Strong organic growth of 35.0% with significant traction in group sales volume coupl
Slide 27: Fully on track to deliver our guidance
Fully on track to deliver our guidance FY 24E Mid-term (2027 target) • We expect to grow organically at high-single digit in 2023-27E, with • High teens organic growth above mid-single digit yearly growth in 2025-27E Revenue • Around 30% total growth including acquisitions • We expect a near doublin
Slide 28: Key developments post H1 2024
Key developments post H1 2024 2 synergistic acquisitions completed in August Ecovadis Silver Medal Closing: July 31st, 2024 Closing: September 1st, 2024 Silver Medal awarded on August 5th, 2024 Country: UK Country: Canada Placed Exosens in the top 15% worldwide 2023 sales1: GBP 11.0m 2023 sales2: CA
Slide 29: Next period's key priorities / milestones
Next period’s key priorities / milestones Amplification D&I M&A Execute increased capacity plan Detection: Increase design-in Start integration of Centronic and penetration of Tier 1 customers in LR Tech Continue development of Next Gen electron microscopy and product towards official commercial sem
Slide 30: Q&A
Q&A © EXOSENS restricted & confidential
Slide 31: Appendix
Appendix © EXOSENS restricted & confidential
Slide 32: Income statement
Income statement In €m H1 2023 H1 2024 Revenue 125.0 186.9 Purchases consumed (30.5) (45.6) Other purchases and external expenses (24.1) (33.9) Taxes (0.9) (1.2) Personnel expenses (38.9) (55.5) Other operating income / (expenses) 1.5 (0.6) Depreciation and amortisation (11.5) (15.5) o/w PPA amortis
Slide 33: Cash flow statement
Cash flow statement In €m H1 2023 H1 2024 Profit / (loss) 8.3 2.9 Net financial result 9.5 25.7 Corporate income taxes 1.4 2.1 Depreciation and amortisation 11.5 15.5 Other income and expenses 1.3 2.9 Taxes paid (3.0) (1.6) Change in net working capital (13.2) (7.7) Cash flow from operating activiti
Slide 34: Balance sheet – assets
Balance sheet – assets In €m 31-Dec-2023 H1 2024 Goodwill 174.3 174.3 Intangible assets 202.4 198.8 Tangible assets 72.1 79.4 Right-of-use of leases 10.8 9.9 Investment in associates 3.4 3.4 Financial assets and other long-term investments 0.7 1.2 Deferred tax assets 0.0 1.5 Long-term assets 463.7 4
Slide 35: Balance sheet – equity and liabilities
Balance sheet – equity and liabilities In €m 31-Dec-2023 H1 2024 Share capital 1.9 21.6 Additional paid-in capital 188.1 340.6 Retained earnings 14.1 19.8 Total equity 204.1 382.0 Long-term financial debt 300.8 249.0 Long-term lease liabilities 7.7 7.6 Pension liabilities 7.6 7.7 Provisions and othe
Slide 36: Operating profit bridge
Operating profit bridge In €m H1 2023 H1 2024 Comments Operating Profit 19.2 30.7 Depreciation, amortisation and impairment - net 11.1 15.9 1 Costs mainly attributable to consultancy & advisory expenses for M&A 1 2 Other income and expenses 1.4 3.9 2 Costs incurred in the context of the IPO EBITDA 3
Slide 37: Financial glossary
FINANCIAL GLOSSARY Organic growth is the growth in revenue achieved by the Group on a like-for-like basis, which corresponds to revenue achieved during period “n” by all the companies included in the Group’s scope of consolidation at the end of period “n1” (excluding any contribution from companies